Okay, great.
It underlines having a diverse portfolio of seven vaccine candidates, with 400 million doses. It was a smart strategy, knowing that there would probably be bumps in the road with supply and that maybe, with some of the delays, it would be smart to take an additional look at some of the vaccines before they were released. Was that a good strategy?